References
- Burnell P , SmallT, DoigS, JohalB, JenkinsR, GibsonGJ. Ex vivo product performance of Diskus™ and Turbuhaler™ inhalers using inhalation profiles from patients with severe chronic obstructive pulmonary disease. Respiratory Med.95, 324–330 (2001).
- Larhrib H , MartinGP, MarriottC, PrimeD. The influence of carrier and drug morphology on drug delivery from dry powder formulations. Int. J. Pharm.257, 283–296 (2003).
- Larhrib H , ZengXM, MartinGP, MarriottC, PritchardJ. The use of different grades of lactose as a carrier for aerosolised salbutamol sulphate. Int. J. Pharm.191, 1–14 (1999).
- Kaialy W , TicehurstM, NokhodchiA. Dry-powder inhalers: mechanistic evaluation of lactose formulations containing salbutamol sulphate. Int. J. Pharm.423, 184–194 (2012).
- Kaialy W , AlhalawehA, VelagaSP, NokhodchiA. Influence of lactose carrier particle size on the aerosol performance of budesonide from a dry-powder inhaler. Powder Technol.227, 74–85 (2012).
- Kaialy W , MartinGP, TicehurstMDet al. Characterization and deposition studies of recrystallized lactose from binary mixtures of ethanol/butanol for improved drug delivery from dry-powder inhalers. AAPS J. 13, 30–43 (2011).
- Patton JS , PlatzRM. Pulmonary delivery of peptides and proteins for systemic action. Adv. Drug Deliv. Rev.8, 179–228 (1992).
- Steckel H , FurkertFH. Endotoxin testing in inhalation grade lactose – a useful quality parameter? Int. J. Pharm.275, 211–215 (2004).
- Glasnapp A . Alternatives for the lactose-intolerant patient. Int. J. Pharm.2, 412–413 (1998).
- Steckel H , BolzenN. Alternative sugars as potential carriers for dry powder inhalations. Int. J. Pharm.270, 297–306 (2004).
- Kaialy W , NokhodchiA. Treating mannitol in a saturated solution of mannitol: a novel approach to modify mannitol crystals for improved drug delivery to the lungs. Int. J. Pharm.448, 58–70 (2013).
- Kaialy W , NokhodchiA. Freeze-dried mannitol for superior pulmonary drug delivery via dry-powder inhaler. Pharm. Res.30, 458–477 (2013).
- Kaialy W , LarhribH, TicehurstMD, NokhodchiA. Influence of batch cooling crystallization on mannitol physical properties and drug disposition from dry-powder inhalers. Cryst. Growth Des.12, 3006–3017 (2012).
- Kaialy W , MartinGP, TicehurstMD, MominMN, NokhodchiA. The enhanced aerosol performance of salbutamol from dry powders containing engineered mannitol as excipient. Int. J. Pharm.392, 178–188 (2010).
- Donovan MJ , SnythHDC. Influence of size and surface roughness of large lactose carrier particles in dry-powder inhaler formulations. Int. J. Pharm.402, 1–9 (2010).
- Islam N , StewartP, LarsonI, HartleyP. Effect of carrier size on the dispersion of salmeterol xinofoate from interactive mixtures. J. Pharm. Sci.93, 1030–1038 (2004).
- Hooton JC , JonesMD, PriceR. Predicting the behaviour of novel sugar carriers for dry-powder inhaler formulations via the use of a cohesive–adhesive force balance approach. J. Pharm. Sci.95, 1288–1297 (2006).
- Begat P , MortonDA, StaniforthJN, PriceR. The cohesive–adhesive balances in dry-powder inhaler formulations I: direct quantification by atomic force microscopy. Pharm. Res.21, 591–597 (2004).
- Kaialy W , NokhodchiA. Engineered ternary additives improve dispersion of lactose-salbutamol sulphate dry powder inhalations. AAPS J. (2013) (In Press).